CN105616661A - Traditional Chinese medicine composition for treating Parkinson's disease and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating Parkinson's disease and preparation method and application thereof Download PDFInfo
- Publication number
- CN105616661A CN105616661A CN201610100102.XA CN201610100102A CN105616661A CN 105616661 A CN105616661 A CN 105616661A CN 201610100102 A CN201610100102 A CN 201610100102A CN 105616661 A CN105616661 A CN 105616661A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- medicine composition
- traditional chinese
- preparation
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating the Parkinson's disease and a preparation method and application thereof.The traditional Chinese medicine composition is prepared from herba houttuyniae, semen myristicae, notopterygium roots, Rutaceae Acronychia pedunculata and corydalis tubers.The raw materials are cleaned and air-dried, smashing and mixing are carried out, water is added for decoction twice, an extracting solution is subjected to alcohol extraction twice with an ethanol solution, extracting solutions are combined and are enriched and purified with macroreticular resin, elution is carried out with an ethanol solution, eluant is subjected to vacuum concentration to form liquid, and vacuum drying and smashing are carried out.It is proved through animal tests and cell tests that the traditional Chinese medicine composition has a good clinical curative effect on the Parkinson's disease, no damage of the traditional Chinese medicine composition to the functions of the heart, liver and kidney and the blood system is found in the treatment process, and clinical application is safe.The traditional Chinese medicine composition can be prepared into dripping pills, capsules, tablets and granules, the medicine effect is good, effect taking is fast, the dose for a patient is small, and safety and reliability are achieved.
Description
Technical field
The present invention relates to Chinese medicine composition field, specifically one treats Parkinsonian Chinese medicine composition and its preparation method and application.
Background technology
Parkinson disease, also known as Parkinsonism, are a kind of common central nervous system degenerative diseases, clinically with extrapyramidal movement disorder for feature, show as bradykinesia, static tremor and tetanic, dysautonomia and dementia, its sickness rate increases with the age and increases. Current Therapeutic Method is based on relief of symptoms, but relapse rate height prognosis is unsatisfactory, generally requires life-long therapy, brings serious society and financial burden to the mankind, so urgent needs finds prevention and the treatment effective Chinese medicine composition of parkinson.
At present, market there is no the Parkinsonian effective Chinese patent medicine for the treatment of. Parkinsonian treatment is mainly operative treatment and the big class of Drug therapy two. Owing to operation and DOPA surrogate therapeutic exist serious destructiveness and side effect, find can prevent and delay the Therapeutic Method of disease process become in the urgent need to. Parkinson disease are infirmitiess of age, be under human senescence state neuroendocrine factors lack of proper care coefficient result, Chinese medicine be by regulate body integral status and work, mild in medicine property and, toxic and side effects is little. If simple Chinese medicine can effectively control Early Parkinson's disease symptom; thus avoiding the toxic and side effects of Western medicine; it is greatly enhanced the compliance that patient takes medicine; simultaneously; the aspect achievements in research such as Chinese medicine composition is at protection neurocyte, it is suppressed that response to oxidative stress, anti-excitatory toxicity are long-term treatment parkinson disease; effectively controlling parkinson disease process to have laid a good foundation, this is the developing direction of traditional Chinese medicine in treatment of Parkinson disease. Therefore, it is still necessary to continue the Parkinsonian Chinese medicine composition for the treatment of that research and development are new.
Summary of the invention
It is an object of the invention to provide one and treat Parkinsonian Chinese medicine composition and its preparation method and application, with the problem solving to propose in above-mentioned background technology.
For achieving the above object, the present invention provides following technical scheme:
A kind of described Parkinsonian Chinese medicine composition for the treatment of, is prepared from by the raw material of following weight portion: Herba Houttuyniae 20��24 parts, Semen Myristicae 25��27 parts, Rhizoma Et Radix Notopterygii 30��36 parts, Lignum Dalbergiae Odoriferae 9��11 parts, Rhizoma Corydalis 8��10 parts.
A kind of described preparation method treating Parkinsonian Chinese medicine composition, concrete preparation process is as follows:
(1) above-mentioned each raw material is cleaned up, dry, after pulverizing, cross 240��260 mesh sieves, mix homogeneously;
(2) add the water of mixed material weight 8��10 times, first boil 3��5min, continuing decoction 30��40min, filtering, again adding the water of 6��8 times, decocting 32��36min, filtering, merging filtrate, obtain extracting solution A, standby;
(3) being added by extracting solution A in the alcoholic solution that volume fraction is 92��96%, heating and refluxing extraction 2��3 times, the volume of alcoholic solution is 8��10 times of extracting solution A volume, and each extraction time is 1��2h, and united extraction liquid obtains alcohol extract B;
(4) enriching and purifying macroporous resin is adopted, with the alcoholic solution eluting that volume fraction is 80��85%, it is the liquid of 1.10��1.20 that eluent is evaporated to relative density at 60��64 DEG C, at 60��65 DEG C, vacuum drying under 0.01��0.02KPa, it is crushed to the powder of 300��320 orders.
As the further scheme of the present invention: the macroporous adsorbent resin in described step (4) is the one in AB-8 macroporous adsorbent resin, X-5 macroporous adsorbent resin, DM-301 macroporous adsorbent resin or NKA-9 macroporous adsorbent resin.
A kind of described Chinese medicine composition extract accepts the application in preparation treatment anti-parkinson drug of the pharmaceutical composition of additives as active component on pharmacopedics.
As the further scheme of the present invention: described treatment anti-parkinson drug makes the solid preparation of granule, tablet, drop pill, injectable powder or capsule.
Compared with prior art, the invention has the beneficial effects as follows: prove through animal experiment and test cell line, treatment parkinson disease are had good clinical efficacy by Chinese medicine composition of the present invention, do not find that the heart, Liver and kidney function and blood system are had infringement, clinical practice safety by it in therapeutic process. Chinese medicine composition of the present invention can make drop pill, capsule, tablet, granule, good drug efficacy, and rapid-action, patient's dose is little, taking convenience, it is possible to treatment is trembled, and to parkinsonian stable curative effect, takes effect rapidly, can reach the effect for the treatment of both the principal and secondary aspects of a disease.
Detailed description of the invention
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described, it is clear that described embodiment is only a part of embodiment of the present invention, rather than whole embodiments. Based on the embodiment in the present invention, the every other embodiment that those of ordinary skill in the art obtain under not making creative work premise, broadly fall into the scope of protection of the invention.
Embodiment 1
Treat Parkinsonian Chinese medicine composition, the raw material of following weight portion be prepared from: Herba Houttuyniae 20 parts, Semen Myristicae 27 parts, Rhizoma Et Radix Notopterygii 30 parts, Lignum Dalbergiae Odoriferae 11 parts, Rhizoma Corydalis 8 parts.
The preparation process treating Parkinsonian Chinese medicine composition in above-described embodiment is as follows:
(1) above-mentioned each raw material is cleaned up, dry, after pulverizing, cross 240 mesh sieves, mix homogeneously;
(2) add the water of mixed material weight 8 times, first boil 3min, continue to decoct 30min, filtration, again add the water of 6 times, decoct 32min, filter, merging filtrate, obtain extracting solution A, standby;
(3) being added by extracting solution A in the alcoholic solution that volume fraction is 92%, heating and refluxing extraction 3 times, the volume of alcoholic solution is 8 times of extracting solution A volume, and each extraction time is 1h, and united extraction liquid obtains alcohol extract B;
(4) adopting AB-8 enriching and purifying macroporous resin, with the alcoholic solution eluting that volume fraction is 80%, it is the liquid of 1.10��1.20 that eluent is evaporated to relative density at 60 DEG C, at 60 DEG C, vacuum drying under 0.01KPa, is crushed to the powder of 300 orders.
Embodiment 2
Treat Parkinsonian Chinese medicine composition, the raw material of following weight portion be prepared from: Herba Houttuyniae 22 parts, Semen Myristicae 26 parts, Rhizoma Et Radix Notopterygii 33 parts, Lignum Dalbergiae Odoriferae 10 parts, Rhizoma Corydalis 9 parts.
The preparation process treating Parkinsonian Chinese medicine composition in above-described embodiment is as follows:
(1) above-mentioned each raw material is cleaned up, dry, after pulverizing, cross 250 mesh sieves, mix homogeneously;
(2) add the water of mixed material weight 9 times, first boil 4min, continue to decoct 35min, filtration, again add the water of 7 times, decoct 34min, filter, merging filtrate, obtain extracting solution A, standby;
(3) being added by extracting solution A in the alcoholic solution that volume fraction is 94%, heating and refluxing extraction 3 times, the volume of alcoholic solution is 9 times of extracting solution A volume, and each extraction time is 1.5h, and united extraction liquid obtains alcohol extract B;
(4) adopting X-5 enriching and purifying macroporous resin, with the alcoholic solution eluting that volume fraction is 82%, it is the liquid of 1.10��1.20 that eluent is evaporated to relative density at 62 DEG C, at 63 DEG C, vacuum drying under 0.015KPa, is crushed to the powder of 310 orders.
Embodiment 3
Treat Parkinsonian Chinese medicine composition, the raw material of following weight portion be prepared from: Herba Houttuyniae 24 parts, Semen Myristicae 25 parts, Rhizoma Et Radix Notopterygii 36 parts, Lignum Dalbergiae Odoriferae 9 parts, Rhizoma Corydalis 10 parts.
The preparation process treating Parkinsonian Chinese medicine composition in above-described embodiment is as follows:
(1) above-mentioned each raw material is cleaned up, dry, after pulverizing, cross 260 mesh sieves, mix homogeneously;
(2) add the water of mixed material weight 10 times, first boil 5min, continue to decoct 40min, filtration, again add the water of 8 times, decoct 36min, filter, merging filtrate, obtain extracting solution A, standby;
(3) being added by extracting solution A in the alcoholic solution that volume fraction is 96%, heating and refluxing extraction 2 times, the volume of alcoholic solution is 10 times of extracting solution A volume, and each extraction time is 2h, and united extraction liquid obtains alcohol extract B;
(4) adopting DM-301 enriching and purifying macroporous resin, with the alcoholic solution eluting that volume fraction is 85%, it is the liquid of 1.10��1.20 that eluent is evaporated to relative density at 64 DEG C, at 65 DEG C, vacuum drying under 0.02KPa, is crushed to the powder of 320 orders.
Experimental example 1: cell experiment
(1) experimental cell strain: PC12 cell is purchased from Shanghai cell institute of the Chinese Academy of Sciences
(2) Experimental agents: MPP+ is purchased from SIGMA-RBI company, Chinese medicine composition powder of the present invention (Chinese medicine composition according to embodiment 2)
(3) experimental technique: PC12 cell is made into single cell suspension, with 5 �� 104/ ML is inoculated in 96 well culture plates, liquid is changed after cultivating 24h continuously, every hole is separately added into the Chinese medicine composition diluent of the present invention of variable concentrations so that it is final concentration is 2.5,5,10,20,40,80 �� g/ml respectively, is simultaneously introduced 300 ��m of ol/LMPP+ solution of final concentration. After being cultivated for 48h, every hole adds MTT solution (5mg/ml) 20 �� l, 370C and hatches 4h. Carefully being emptied culture medium after terminating cultivation, every hole adds 150 �� 1DMSO, and vibrate 10min, makes crystallization fully dissolve. Microplate reader detects every hole in 490nm place absorption value, calculates cell survival rate, and experimental result is in Table 1, table 2. Statistical procedures data represent with mean �� standard deviation (x �� s), carry out statistical procedures with t inspection.
The impact (x �� s) of the PC12 cell injury that MPP+ is induced by the Chinese medicine composition of the present invention of table 1 variable concentrations
Note: compare with model group, * p < 0.05
The impact (x �� s) of the PC12 cell injury that MPP+ is induced by the Chinese medicine composition of the present invention of table 2 variable concentrations
Note: compare with model group, * p < 0.05
Can be seen that from experimental result, the impact of the cell injury that MPP+ induces is also existed obvious difference by the Chinese medicine composition of the present invention of variable concentrations, compared with model group, 20,40 �� g/ml Chinese medicine composition group cell survival rates of the present invention are apparently higher than model group (P < 0.05, statistically significant), illustrate that 20,40 �� g/ml Chinese medicine compositions of the present invention can substantially reduce the damage effect of MPP+, so that cell survival rate has raising by a relatively large margin.
Experimental example 2: pharmacodynamic experiment
1, animal packet and modeling method: 100 mices, is randomly divided into low dose group, high dose group, model group, blank group, often group 25. Model group and high and low dose group lumbar injection every day MPTP-HCl (tetrahydropyridine hydrochlorate) 30mg/ (kg bw) (being equivalent to 25mg/kgMPTP), injection 5 days, cause PD model continuously. The normal saline of blank group lumbar injection equivalent. Within 6th day, start high and low dose group and give the normal saline that amount respectively 180mg/ (kg bw)/d, 45.5mg/ (kg the bw)/d of Chinese medicine composition of the present invention, model group and blank group give equivalent, successive administration 20 days.
2, general behavior is observed: observe mice general behavior performance after abdominal cavity gives MPTP modeling, with or without abnormal response.
Result: after abdominal cavity gives MPTP (25mg/ (kg bw)) several minutes, the general behavior performance of MPTP model group mice is abnormal compared with matched group, and following change occur in great majority: tremble, step-length shortenings, slow movement, to erect hair, to external world irritant reaction low etc. Tremble and show as locality, such as lower jaw, extremity or afterbody.
3, Grasping clubglass test: the foam plastics bead that a diameter is 2cm is fixed on the rod top of a thick lcm of root length 40cm, rod twines 2 layers of gauze with anti-slip. Holding mouse tail and its head is placed in downwards pole top (being as the criterion as on ball with the double; two hind leg of mice), allow it naturally climb down, mice is completely long for climbing to platform at the bottom of double; two forelimb contact poles in pole top from standing, and records the pole-climbing time. Within 5th day, the 10th day, the 15th day and the 20th day, carry out after starting administration.
Result: from the 15th day of administration, the model group pole-climbing time is significantly more than blank group, and ((P < 0.05), from the 5th day, the pole-climbing time of high and low dose group was less than model group, but there was no significant difference.
4, striatum DA and HVA assay
(1) drawing materials and sample treatment: every 10 mices of group selection, broken end takes brain, peels off bilateral striatum, weighs, Liquid nitrogen storage. Take each group of mouse striaturn, add 600 �� L0.4mol L-1Perchloric acid removing protein, prepares homogenate, 15000rpm, 4 DEG C of centrifugal 15min, takes supernatant in-70 DEG C of preservations.
(2) DA assay
Chromatographic condition: chromatographic column ACQUITYUPLCTMBEHC18column (50mm �� 2.lmmid, 1.7 ��m, WatersCorp, Milford, USA), mobile phase 0.1% formic acid acetonitrile: water=4:96, flow velocity 0.3mL/min, column temperature 30 DEG C, sample size is 10 �� L.
Mass Spectrometry Conditions: electric spray ion source (ESI), adopts cation Scanning Detction, and capillary voltage is 1500V, sample taper hole voltage is 40V, and ion source temperature is 100 DEG C, and desolventizing temperature is 352 DEG C, desolventizing throughput is 700L/h, and taper hole throughput is 20L/h.
Selecting m/z is 154.8 (M+H+), and the ES+ chromatogram of 137.08 (M-OH-) carries out quantitatively jointly. MicromassMarkerLynx software is adopted to carry out chromatographic peak identification and calculated by peak area.
(3) HVA assay
Chromatographic condition: chromatographic column ACQUITYUPLCTMBEHC18column (50mm �� 2.lmmid, 1.7 ��m, WatersCorp, Milford, USA), mobile phase 0.1% formic acid acetonitrile: water=12:88, flow velocity 0.3mL/min, column temperature 30 DEG C, sample size is 10 �� L.
Mass Spectrometry Conditions: electric spray ion source (ESI), adopts cation Scanning Detction, and capillary voltage is 1500V, sample taper hole voltage is 40V, and ion source temperature is 100 DEG C, and desolventizing temperature is 352 DEG C, desolventizing throughput is 700L/h, and taper hole throughput is 20L/h.
Selecting m/z is 181.04 (M-H+), and 227.05 (M+HC00-), the ES-chromatogram of 363.09 (M+M-H+) carries out quantitatively jointly. MicromassMarkerLynx software is adopted to carry out chromatographic peak identification and calculated by peak area.
Result: model group striatum DA and metabolite HVA content thereof are considerably less than blank group (P < 0.05), low dose group striatum DA level is significantly more than model group (P < 0.05), high dose group striatum DA level is also more than model group, but there was no significant difference. Model group, blank group, high dose group, low dose group stricture of vagina shape HVA/DA ratio are sequentially reduced, but each group does not all have significant difference.
From above-mentioned experiment it can be seen that MPTP brings out mice occurs that the performance of Parkinsonian symptoms is clearly, in behavioristics, its muscular tremor, voluntary movement reduces, sports coordination ability decline can show from general behavior, creep test observed. On this basis, giving Chinese medicine composition of the present invention and intervene, compared with model group, the administration group pole-climbing time all shortens to some extent, and this shows that the pole-climbing behavior of PD mice is had a degree of improvement result by Chinese medicine composition of the present invention. Low dose group striatum DA level, apparently higher than model group, illustrates that Chinese medicine composition of the present invention can increase the content of striatum DA in PD model.
Experimental example 3: the animal acute toxicity research of Chinese medicinal composition capsules of the present invention
Select healthy mice, it is administered with gavage method, observe the acute toxic reaction of the capsule prepared by embodiment, tablet, granule and drop pill, the maximum tolerated dose > 16g/kg of result administration respectively, be equivalent to 320 times of clinical application amount. Matched group is to the distilled water of Isodose, and take medicine 7d continuously. Result shows that the general health of white mice is in order, and hair color is smooth, and appetite is normal, defecates without exception, does not occur animal dead phenomenon during whole administration, and after experiment terminates, administration group white mice average weight rate of increase is identical with matched group.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, and when without departing substantially from the spirit of the present invention or basic feature, it is possible to realize the present invention in other specific forms. Therefore, no matter from which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the invention rather than described above limits, it is intended that all changes in the implication of the equivalency dropping on claim and scope included in the present invention.
Claims (5)
1. treat Parkinsonian Chinese medicine composition for one kind, it is characterised in that be prepared from by the raw material of following weight portion: Herba Houttuyniae 20��24 parts, Semen Myristicae 25��27 parts, Rhizoma Et Radix Notopterygii 30��36 parts, Lignum Dalbergiae Odoriferae 9��11 parts, Rhizoma Corydalis 8��10 parts.
2. the preparation method of the Parkinsonian Chinese medicine composition for the treatment of as claimed in claim 1, it is characterised in that concrete preparation process is as follows:
(1) above-mentioned each raw material is cleaned up, dry, after pulverizing, cross 240��260 mesh sieves, mix homogeneously;
(2) add the water of mixed material weight 8��10 times, first boil 3��5min, continuing decoction 30��40min, filtering, again adding the water of 6��8 times, decocting 32��36min, filtering, merging filtrate, obtain extracting solution A, standby;
(3) being added by extracting solution A in the alcoholic solution that volume fraction is 92��96%, heating and refluxing extraction 2��3 times, the volume of alcoholic solution is 8��10 times of extracting solution A volume, and each extraction time is 1��2h, and united extraction liquid obtains alcohol extract B;
(4) enriching and purifying macroporous resin is adopted, with the alcoholic solution eluting that volume fraction is 80��85%, it is the liquid of 1.10��1.20 that eluent is evaporated to relative density at 60��64 DEG C, at 60��65 DEG C, vacuum drying under 0.01��0.02KPa, it is crushed to the powder of 300��320 orders.
3. the preparation method of the Parkinsonian Chinese medicine composition for the treatment of according to claim 2, it is characterized in that, the macroporous adsorbent resin in described step (4) is the one in AB-8 macroporous adsorbent resin, X-5 macroporous adsorbent resin, DM-301 macroporous adsorbent resin or NKA-9 macroporous adsorbent resin.
4. the pharmaceutical composition that Chinese medicine composition extract accepts additives as active component on pharmacopedics as defined in claim 1 treats the application in anti-parkinson drug in preparation.
5. application according to claim 4, it is characterised in that described treatment anti-parkinson drug makes the solid preparation of granule, tablet, drop pill, injectable powder or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610100102.XA CN105616661A (en) | 2016-02-24 | 2016-02-24 | Traditional Chinese medicine composition for treating Parkinson's disease and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610100102.XA CN105616661A (en) | 2016-02-24 | 2016-02-24 | Traditional Chinese medicine composition for treating Parkinson's disease and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105616661A true CN105616661A (en) | 2016-06-01 |
Family
ID=56032273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610100102.XA Pending CN105616661A (en) | 2016-02-24 | 2016-02-24 | Traditional Chinese medicine composition for treating Parkinson's disease and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105616661A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239598A (en) * | 2012-02-13 | 2013-08-14 | 杨明会 | Traditional Chinese medicine composition for treatment of Parkinson's disease and application thereof |
| CN103987395A (en) * | 2011-10-12 | 2014-08-13 | 庆熙大学校产学协力团 | Pharmaceutical composition for preventing and treating dementia, parkinson's disease or epilepsy, containing houttuynia cordata thunb. Extract as active ingredient |
-
2016
- 2016-02-24 CN CN201610100102.XA patent/CN105616661A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103987395A (en) * | 2011-10-12 | 2014-08-13 | 庆熙大学校产学协力团 | Pharmaceutical composition for preventing and treating dementia, parkinson's disease or epilepsy, containing houttuynia cordata thunb. Extract as active ingredient |
| CN103239598A (en) * | 2012-02-13 | 2013-08-14 | 杨明会 | Traditional Chinese medicine composition for treatment of Parkinson's disease and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 毛丽军，宁侠，鲁嵒: "《神经系统疾病验方妙用》", 30 April 2010, 科学技术文献出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6091651B2 (en) | Pharmaceutical composition for treating headache and method for preparing the same | |
| JP6880236B2 (en) | Chinese herbal extract effective for depression and its preparation method and use | |
| CN110742972B (en) | Traditional Chinese medicine composition with cognitive improvement effect and preparation method thereof and traditional Chinese medicine preparation | |
| CN102014931A (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN102100825B (en) | Chinese medicine composition for treating pains and preparation method thereof | |
| CN104225006A (en) | Traditional Chinese medicine composition capable of invigorating Qi and relaxing bowels | |
| CN103169788A (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| CN101797307B (en) | Phenethyl alcohol glycoside-containing callicarpa kochiana extractive and preparation method thereof | |
| CN1748783A (en) | Dismenorrhea preparation and new preparing method | |
| CN104510853B (en) | A kind of Chinese medicinal effective-part composition for the treatment of dysmenorrhes and uses thereof | |
| CN105726985A (en) | Traditional Chinese medicine for treating Parkinson's disease and preparation method thereof | |
| CN102526214B (en) | Traditional Chinese medicine preparation for treating angioneurotic headache and migraine | |
| CN1704113A (en) | Chinese traditional medicinal preparation containing red sange root and safflower for treating cardiovascular and cerebrovascular diseases and preparing process thereof | |
| CN105616661A (en) | Traditional Chinese medicine composition for treating Parkinson's disease and preparation method and application thereof | |
| CN104055812A (en) | Composition having anti-depression effect as well as preparation method and use thereof | |
| CN100479816C (en) | Gingko total terpene lactone compounded medicinal composition, and preparing method and use thereof | |
| CN102283920B (en) | Medicinal composition for treating parkinson disease as well as preparation method and application thereof | |
| CN102166282B (en) | Anti-allergic or desensitized pharmaceutical composition | |
| CN104510854A (en) | Traditional Chinese medicinal composition for treating dysmenorrhea of women and application of traditional Chinese medicinal composition | |
| CN111643540A (en) | Eucommia ulmoides extract for treating lumbar muscle strain and preparation method thereof | |
| CN104258034A (en) | Traditional Chinese medicine composition for boosting immunity | |
| CN1278731C (en) | Compound bupleurum root medicinal preparation | |
| CN107898828A (en) | Pepper Bi roots of grass compositions dichloromethane extraction position and its preparation method and application | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN105663529A (en) | Traditional Chinese medicinal composition for treating depression and preparation method of traditional Chinese medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160601 |
|
| WD01 | Invention patent application deemed withdrawn after publication |